The increasing evidence that altered gut microbiota correlate with non-motor features of PD rests on the premise of the need for more evidence to be generated for possible therapeutic strategies to be unveiled
Using copper to improve the well-being of the skin
Tirzepatide (a dual GIP/GLP-1 agonist) showed even greater reductions, around 22%, in the SURMOUNT clinical program
Here are a few groups of people who may benefit most from these programs: Individuals with a BMI of 27 or higher who also have weight-related health issues like type 2 diabetes, high blood pressure, or high cholesterol Those struggling with appetite control or frequent cravings, especially when diet and exercise alone havent worked People looking for injections for weight loss who want to avoid or delay bariatric surgery GLP-1 weight loss programs offer a supportive, medication-assisted approach that works best when paired with lifestyle changes
Its overall beneficial effects have led Canada and the US to mandate the fortification of grain-based food products with folic acid since 1998 [35]
Incorporating those early digital biomarkers into adaptive algorithms could allow dose intensification or timely switch to alternative therapies